Tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or anti-tumour necrosis factor (TNF) showed no significant differences in flare ratios, disease activity, functional ability, and quality of life (QoL) between both tapering strategies during the first 12 months of follow-up. Early detection of RA, early initiation of ‘intensive’ therapy, and a treat-to-target (T2T) approach have led to substantial improvements in clinical and radiographic outcomes in RA over the last two decades. This has resulted in 50% to 60% of early RA patients achieving sustained remission during the first year of follow-up. Although current guidelines recommend to consider tapering treatment, an optimal approach to gradually de-escalate csDMARDs or bDMARDs is still lacking substantial evidence.
Van Mulligen et al. aimed to evaluate the effectiveness of two tapering strategies: gradual tapering of csDMARDs and TNF therapy during one year of follow-up. This study was s...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Systemic Lupus Erythematosus: Baricitinib May Be Potential Therapy, and Clinical Benefit of Ustekinumab Next Article
The Role of bDMARDs in Psoriatic Arthritis »
Table of Contents: EULAR 2018
Psoriasis and Psoriatic Arthritis
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.